Get the Stockscreener App
280.61
0.67%
1.85
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $280.61, with a volume of 2.86M.
It is up +0.67% in the last 24 hours and down -12.97% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$278.76
Open:
$277.67
24h Volume:
2.86M
Relative Volume:
1.49
Market Cap:
$149.76B
Revenue:
$32.53B
Net Income/Loss:
$4.23B
P/E Ratio:
19.94
EPS:
14.07
Net Cash Flow:
$6.28B
1W Performance:
-6.32%
1M Performance:
-12.97%
6M Performance:
-10.41%
1Y Performance:
+5.49%
1-Day Range:
$275.56
$281.60
1-Week Range:
$275.56
$307.43
52-Week Range:
$260.52
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| AMGN | 279.95 | 149.76B | 32.53B | 4.23B | 6.28B | 14.07 |
| LLY | 729.73 | 691.13B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 102.63 | 455.61B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 153.00 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.57 | 293.73B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 96.54 | 243.41B | 63.17B | 12.15B | 14.84B | 1.80 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Jennison Associates LLC Sells 78,759 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Strategy Asset Managers LLC Sells 2,761 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen, Coke Set Aside Only Fraction of Billions They May Owe IRS - Bloomberg Tax
(AMGN) Investment Report - Stock Traders Daily
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen Stock Has High Implied Volatility. An Iron Condor Takes Advantage. - Yahoo! Voices
Amgen Inc. (NASDAQ:AMGN) Shares Sold by PNC Financial Services Group Inc. - MarketBeat
Second Half Financial Partners LLC Buys Shares of 10,591 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Banque Cantonale Vaudoise Cuts Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Prospera Financial Services Inc Has $9.79 Million Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Stake Lessened by Princeton Capital Management LLC - MarketBeat
Amgen Inc. (NASDAQ:AMGN) is Smead Capital Management Inc.'s 6th Largest Position - MarketBeat
Meeder Asset Management Inc. Increases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
MAI Capital Management Sells 5,862 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Intravenous Solutions Market to Surpass USD 23.96 Billion by 2031 | SkyQuest Technology - Benzinga
AMG National Trust Bank Trims Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Amgen Sells Off: Keep Calm And Buy The Dip (NASDAQ:AMGN) - Seeking Alpha
Napa Wealth Management Acquires New Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Is Amgen Inc. (AMGN) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Aljian Capital Management LLC Grows Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Short Interest Update - MarketBeat
Thrivent Financial for Lutherans Trims Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Swiss National Bank Grows Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Atlanta Consulting Group Advisors LLC Makes New $796,000 Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Natixis Advisors LLC Has $94.32 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Sawgrass Asset Management LLC Sells 11,850 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
GSA Capital Partners LLP Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Kinsale Capital Group Inc. Raises Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mizuho Securities USA LLC Has $25.16 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Kentucky Retirement Systems Has $12.06 Million Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious - MSN
Northcape Wealth Management LLC Increases Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
The three-year decline in earnings for Amgen NASDAQ:AMGN) isn't encouraging, but shareholders are still up 50% over that period - Yahoo Finance
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Amgen Inc (AMGN) Stock Price, Trades & News - GuruFocus.com
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Amazon.com Inc., Amgen share losses lead Dow's 275-point drop - MSN
Dow falls nearly 400 points on losses for shares of Amgen, Amazon.com Inc. - MSN
Amgen, Amazon.com Inc. share losses lead Dow's 288-point drop - MSN
A Journey of Courage: Empowering Others with Gastric Cancer - Amgen
Merck, Amgen share losses lead Dow's 168-point drop - MarketWatch
Amgen (NASDAQ:AMGN) Coverage Initiated by Analysts at Wolfe Research - MarketBeat
Amgen speaks out about bone density concerns with obesity drug - Clinical Trials Arena
Amgen (NASDAQ:AMGN) Stock Rating Upgraded by Citigroup - MarketBeat
Amgen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 - PR Newswire
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate - Yahoo Finance
ING Groep NV Reduces Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Dec 04 '23 |
Sale |
273.03 |
2,096 |
572,276 |
10,874 |
0.97%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):